4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2.

By J. Talley, David L. Brown, J. Carter, M. Graneto, C. Koboldt, J. Masferrer, W. Perkins, R. Rogers, A. Shaffer, Yan Y. Zhang and 2 more. Journal of Medicinal Chemistry, 2000

617 citations recorded by the source corpus.

Subfields: Organic Chemistry, Pharmacology

View Paper: https://www.semanticscholar.org/paper/1a098c659120a401d294734eaa24ea643e81e29a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

1. P. Rao
2. E. Knaus

Citations in the corpus

• Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. (2008, background): “Low levels of the hydroxymethyl metabolite 19 has also been detected in humans (100).”
• Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition (2004, background): “Valdecoxib (Bextra), the successor to celecoxib, was recently approved in the United States for treatment of the signs and symptoms of OA, RA, and menstrual pain (Talley et al., 2000).”